Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Neuren Technologies raises guidance for H1 2026 and announces dividend

As of June 30, Neuren reported AUD 287 million in cash and USD 23.1 million in license revenue for the half-year, and confirmed an annual license revenue guidance of USD 53–56 million. The company is launching a dividend program with a fully franked interim dividend of AUD 0.15 per share and expects an available dividend pool of AUD 48–51.6 million. Commercially, DAYBUE supports cash generation, while the phase‑III KOALA study of NNZ‑2591 is progressing (15 sites activated, recruitment ongoing). Management emphasises financial coverage without a capital raise and keeps the cost estimate for the NNZ‑2591 program at USD 80–90 million. » More on de.investing.com
Neuren Pharma shares surge after patent win for Pitt Hopkins Syndrome treatment

Neuren Pharma's stock rose over 11% following the grant of a patent for its drug NNZ-2591 to treat Pitt Hopkins Syndrome, a rare neurodevelopmental disorder. Clinical trials showed neuropsychological improvements in patients, and there are currently no approved treatments for the condition. Despite recent volatility and a 33% drop in one-year returns, the patent news marks a positive development for the company. » More on themarketonline.com.au

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Neuren Pharmaceuticals has already paid €0.0932 in dividends. The last payout was in October.

Financials

In the last quarter, Neuren Pharmaceuticals had revenue of €20.08m and net profit of €2.94m

(EUR)	June 2026	YoY
Revenue	20.08m	-
Gross profit	20.07m	-
Net profit	2.94m	-
EBITDA	1.66m	-

Fundamentals

Metric	Value
Market capitalization	€1.79bn
Number of shares	126.77m
52-week high/low	€15.08 - €6.76
Dividend yield	4.91%
Dividends TTM	€0.0932
Beta	1.59
P/E ratio	145.29
PEG ratio	-1.69
P/B ratio	8.75
P/S ratio	41.95

Company profile

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.